Abstract
Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.
Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins
Recent Patents on Anti-Cancer Drug Discovery
Title: Anti-Angiogenic Therapy in Renal Cell Carcinoma
Volume: 5 Issue: 1
Author(s): Shree G. Sharma, Sudip Nanda and Santo Longo
Affiliation:
Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins
Abstract: Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.
Export Options
About this article
Cite this article as:
Sharma G. Shree, Nanda Sudip and Longo Santo, Anti-Angiogenic Therapy in Renal Cell Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702181
DOI https://dx.doi.org/10.2174/157489210789702181 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Blood Infusion and the Risk of Haemorrhage in Patients Undergoing Cardiac Surgery with Extracorporeal Circulation
Current Vascular Pharmacology Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Molecular Targeted Approaches for Treatment of Pancreatic Cancer
Current Pharmaceutical Design VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization
Current Medical Imaging Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Current Medicinal Chemistry Angiogenesis and Hypoxia in Glioblastoma: A Focus on Cancer Stem Cells
CNS & Neurological Disorders - Drug Targets Antimicrobial, In Vitro and In Vivo Antineoplastic Activities, Mechanism of Action, Structural and Thermal Properties of a Small-Novel Pharmaceutical Organometallic Chelate
Mini-Reviews in Medicinal Chemistry Tumour Gene Therapy Monitoring Using Magnetic Resonance Imaging and Spectroscopy
Current Gene Therapy Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Gastric Ulcer Complicating a Selective Internal Radiation Therapy (SIRT) Procedure for Colorectal Carcinoma Metastasized to the Liver
Current Radiopharmaceuticals Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective
Current Medicinal Chemistry Relevance of Protein Isoforms in Proteomic Studies
Current Proteomics